JPRN-UMIN000002867招募中2 期
Effect of High-dose Toremifene for premenopausal metastatic breast cancer - Multi04 trial
Multi Hormone Study Group0 个研究点目标入组 25 人开始时间: 2009年12月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Patients have an inadequte organ function. Patients who have had any previous or concomitant malignancy. Patients who have had any other non-malignant systemic diseases (cardiovascular, renal lung, etc. ) that would prevent follow-up
研究者
相似试验
已完成
2 期
Assessment of the Efficacy of High-Dose Toremifene 120mg Therapy for Anastorozole-resistant Postmenopausal Breast Cancer (SBCCSG-11)Postmenopausal breast cancerJPRN-UMIN000000967Saitama Breast Cancer Clinical Study Group (SBCCSG)40
已完成
2 期
Endocrine effects of Toremifene(FARESTON®) and Leuprolide(LEUPLIN®) therapy in premenopausal breast cancer patientspremenopausal breast cancerJPRN-UMIN000004294Kyoto Prefectural University of Medicine50
进行中（未招募）
不适用
Higher Dose taMOxifen in Premenopausal bREast Cancer Patients: a preoperaTive Window TrialNeoplasmsKCT0006681Seoul National University Hospital80
已完成
2 期
Evaluation of the effects of increasing tamoxifen dose on the treatment process in breast cancer patientsBreast cancer.Malignant neoplasm of breastIRCT2015082323734N1Isfahan University of Medical Siences100
已完成
4 期
Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast CancerBreast CancerNCT02344940Shanghai Jiao Tong University School of Medicine104